PDF(Pubmed)
Abstract：
Metastatic BRAFV600E mutated colorectal cancer is associated with poor overall survival and modest effectiveness to standard therapies. Furthermore, survival is influenced by the microsatellite status. Patients with microsatellite-stable and BRAFV600E mutated colorectal cancer have the worst prognosis under the wide range of genetic subgroups in colorectal cancer. Herein, we present a patient case of an impressive therapeutic efficacy of dabrafenib, trametinib, and cetuximab as later-line therapy in a 52-year-old woman with advanced BRAFV600E mutated, microsatellite-stable colon cancer. This patient achieved a complete response after 1 year of triple therapy. Due to skin toxicity grade 3 and recurrent urinary tract infections due to mucosal toxicity, a therapy de-escalation to dabrafenib and trametinib was performed, and the double therapy was administered for further 41 months with ongoing complete response. For 1 year, the patient was off therapy and is still in complete remission.
摘要：
转移性BRAFV600E突变结直肠癌与不良的总生存率和标准疗法的适度有效性相关。此外，生存受到微卫星状态的影响。微卫星稳定和BRAFV600E突变的结直肠癌患者在结直肠癌广泛的遗传亚组下预后最差。在这里，我们提出了一个令人印象深刻的dabrafenib治疗效果的患者案例，曲美替尼,西妥昔单抗作为晚期BRAFV600E突变的52岁女性的后期治疗，微卫星稳定的结肠癌。该患者在1年的三联疗法后达到完全应答。由于3级皮肤毒性和复发性尿路感染由于粘膜毒性，进行了dabrafenib和trametinib的治疗降级，双重治疗又持续41个月,持续完全缓解.一年,患者已停止治疗，仍处于完全缓解状态。
